| Literature DB >> 19607693 |
Christine Schmucker1, Robert Grosselfinger, Rob Riemsma, Gerd Antes, Stefan Lange, Wolf Lagrèze, Jos Kleijnen.
Abstract
BACKGROUND: Amblyopia and amblyogenic factors like strabismus and refractive errors are the most common vision disorders in children. Although different studies suggest that preschool vision screening is associated with a reduced prevalence rate of amblyopia, the value of these programmes is the subject of a continuing scientific and health policy discussion. Therefore, this systematic review focuses on the question of whether screening for amblyopia in children up to the age of six years leads to better vision outcomes.Entities:
Mesh:
Year: 2009 PMID: 19607693 PMCID: PMC2731050 DOI: 10.1186/1471-2415-9-3
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Search strategy in Medline (Ovid)
| 1 | exp CHILD/ | 1129108 |
| 2 | exp INFANT/ | 692510 |
| 3 | (baby or babies or newborn or neonat$).mp. | 536032 |
| 4 | exp schools/ | 49523 |
| 5 | exp CHILD-HEALTH-SERVICES/ | 14438 |
| 6 | exp CHILD-DAY-CARE-CENTERS/ | 3371 |
| 7 | (CHILD$ or ADOLESC$ or JUVENILE$ or MINOR$ or SCHOOL$ or KINDER-GARTEN$ or PRE?SCHOOL$ or NURSER$).ti. | 529317 |
| 8 | (CHILD$ or ADOLESC$ or JUVENILE$ or MINOR$ or SCHOOL$ or KINDER-GARTEN$ or PRE?SCHOOL$ or NURSER$).ab. | 640000 |
| 9 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 | 2031820 |
| 10 | exp strabismus/ | 9863 |
| 11 | exp amblyopia/ | 4081 |
| 12 | exp REFRACTIVE-ERRORS/ | 17635 |
| 13 | ((EYE$ or SIGHT$ or VI-SION$ or VISUAL$) adj4 (PROBLEM$ or DEFECT$ or IMPAIR$ or DEFICI$ or REDUC$)).mp. [mp = ti, ot, ab, nm, hw] | 24836 |
| 14 | (LAZY adj EYE$).mp. [mp = ti, ot, ab, nm, hw] | 14 |
| 15 | (AMBLYOPI$ or SQUINT$ or STRABISM$ or ANISO-METROPI$ or MYOPI$ or HYPERMETROPI$ or ASTIGMATI$ or AM-METROPI$ or HYPER-OPI$).mp. [mp = ti, ot, ab, nm, hw] | 32219 |
| 16 | cataract$.mp. | 40130 |
| 17 | microtropia.mp. | 75 |
| 18 | glaucoma.mp. | 36328 |
| 19 | retinoblastoma.mp. | 14353 |
| 20 | ((heredit$ or retinal or macular) and dystroph$).mp. | 5741 |
| 21 | refract$.mp. [mp = ti, ot, ab, nm, hw] | 77398 |
| 22 | exp vision, low/ | 936 |
| 23 | (SPECTACLES or GLASSES).mp. | 4495 |
| 24 | exp Cataract/ | 16513 |
| 25 | 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 | 208688 |
| 26 | (test or tests or testing).mp. | 1383219 |
| 27 | examination$.mp. | 424043 |
| 28 | ophthalmoscop$.mp. | 9356 |
| 29 | photoscreen$.mp. | 95 |
| 30 | (acuity or red reflex).mp. | 46057 |
| 31 | exp Vision Tests/or exp Visual Acuity/ | 52117 |
| 32 | exp Ophthalmoscopy/ | 5116 |
| 33 | (vision or visual).mp. | 246181 |
| 34 | (test$ or screen$).mp. | 2011737 |
| 35 | 33 and 34 | 58712 |
| 36 | (Hirschberg or Bruckner or motil$ or funduscop$ or cyclopleg$ or skiascop$).mp. [mp = ti, ot, ab, nm, hw] | 67108 |
| 37 | (Auto?refract$ or random?dot or stereoacuity or Snellen or Sheridan-Gardiner).mp. [mp = ti, ot, ab, nm, hw] | 2475 |
| 38 | (Cover?uncover or Alternate cover or Corneal reflex or PhotoScreener or Visiscreen).mp. [mp = ti, ot, ab, nm, hw] | 330 |
| 39 | (Retinomax or Suresight).mp. [mp = ti, ot, ab, nm, hw] | 39 |
| 40 | 26 or 27 or 28 or 29 or 30 or 31 or 32 or 35 or 36 or 37 or 38 or 39 | 1844319 |
| 41 | exp "Sensitivity and Specificity | 211681 |
| 42 | exp Diagnosis/ | 3862053 |
| 43 | diagnos$.mp. | 1268941 |
| 44 | sensitiv$.mp. | 743123 |
| 45 | predict$.mp. | 485857 |
| 46 | accura$.mp. | 238100 |
| 47 | 41 or 42 or 43 or 44 or 45 or 46 | 5133424 |
| 48 | 9 and 25 and 40 and 47 | 9851 |
| 49 | exp Contact Lenses/ | 8117 |
| 50 | exp Eyeglasses/ | 4478 |
| 51 | (refractive adj correct$).ti. | 29 |
| 52 | (refractive adj correct$).ab. | 316 |
| 53 | ((optic$ or vision$ or visual$ or filter$ or lens$ or glass$ or spectacle$) adj3 (occlusion or penali$ or patch$)).ti. | 129 |
| 54 | ((optic$ or vision$ or visual$ or filter$ or lens$ or glass$ or spectacle$) adj3 (occlusion or penali$ or patch$)).ab. | 671 |
| 55 | 49 or 50 or 51 or 52 or 53 or 54 | 12865 |
| 56 | exp clinical trials/ | 190907 |
| 57 | exp research design/ | 212573 |
| 58 | comparative study/or placebos.mp. | 1341575 |
| 59 | exp treatment outcome/ | 283315 |
| 60 | double-blind method/or single-blind method/ | 98869 |
| 61 | ((single or double or triple) adj blind$3).ti. | 20568 |
| 62 | ((single or double or triple) adj blind$3).ab. | 78020 |
| 63 | random$.ti. | 56160 |
| 64 | random$.ab. | 364411 |
| 65 | controlled clinical trial.pt. | 73779 |
| 66 | clinical trial.pt. | 450604 |
| 67 | (clinical adj trial$1).ti. | 25698 |
| 68 | (clinical adj trial$1).ab. | 90789 |
| 69 | (control$3 adj trial$1).ti. | 15725 |
| 70 | (control$3 adj trial$1).ab. | 38465 |
| 71 | randomized controlled trial.pt. | 228874 |
| 72 | exp RANDOM ALLOCATION/ | 57826 |
| 73 | exp PROSPECTIVE STUDIES/ | 213531 |
| 74 | exp Follow-Up Studies/ | 332322 |
| 75 | 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 | 2474586 |
| 76 | 9 and 25 and 55 and 75 | 633 |
| 77 | 9 and 25 and 55 | 1765 |
| 78 | screen$.mp. | 287728 |
| 79 | exp Neonatal Screening/ | 3723 |
| 80 | exp VISION TESTS/ | 19699 |
| 81 | exp MASS SCREENING/ | 77069 |
| 82 | 78 or 79 or 80 or 81 | 309225 |
| 83 | 9 and 25 and 82 | 4644 |
| 84 | 48 or 76 or 83 | 10737 |
| 85 | 48 or 77 or 83 | 11540 |
| 86 | (animals not human).sh. | 4025575 |
| 87 | 85 not 86 | 11140 |
Inclusion criteria
| Children from the general population up to the age of six years | |
| Comparison of screening versus no screening | |
| Randomised controlled trials | |
| Prevalence rate of amblyopia measured by visual acuity | |
Characteristics and outcome measures of the included studies
| Orthoptic screening | 916 (58) | |||
| Retrospective cohort study | Health visitor screening | 1665 (80) | Prevalence of | |
| GP screening | 1378 (81) | |||
| Screening | 808 (82) | |||
| Retrospective cohort study | Prevalence of | |||
| No screening | ||||
| Preschool screening | 1132 (82) | |||
| Randomised controlled clinical trial | 2097 (98)§ | Prevalence of | ||
| Intensive screening | 1408 (69) | |||
| Pseudo-randomised* controlled clinical trial | Less intensive screening | 939 (64) | Prevalence of | |
| Preschool screening | 1019 (67) | |||
| Prospective cohort study | No preschool screening | 5062 | Prevalence of | |
| Psychosocial impairments | ||||
* Pseudorandomisation: last digit in day of mother's date of birth was used to assign children to the intervention group.
† Visual acuity of children treated with occlusion.
‡ Only children who took part at the final assessment (at the age of 7.5 years) were presented in the publication.
§Refers to the number of children who took part in the current screening programme.
Methodological quality of the included studies
| No* | Not specified | Not specified | Not specified | Yes|| | |
| No | Not specified | Not specified# | Not specified | No | |
| No | No | Not specified | No | Yes|| | |
| No† | Yes | Yes | Yes§ | No | |
| No* | Yes | No‡ | Yes§ | No | |
* Retrospective power-analysis.
† Retrospective power-analysis for the outcome measure: visual acuity; prospective power-analysis for a not relevant endpoint.
‡ Parents of screened children were older, higher educated and smoked less during pregnancy; however, results were almost identical after adjustment for confounding factors.
§ For example: duration of breastfeeding, mother's educational level, 1st degree relative with squint, sex.
|| No children were excluded from the analysis.
# It was only noted that the two communities were similar in terms of race, social status, health care facilities, education, nutrition and climate.
** Unclear, if only children who attended the final assessment were analysed.
†† Only children who attended the final assessment were analysed.
Definition and prevalence rate of amblyopia
| VA ≤6/9 | 1.1% (0.7–1.8%) | 1.0% (0.6–1.5%) | Not reported | |
| 1.2% (0.8–1.9%) | Not reported | |||
| VA ≤5/10 | 1.0% | 2.6% | <0.01 | |
| VA ≤5/15 | 0.1% | 1.7% | <0.001 | |
| VA not specified | 0.0% | 0.1% | Not reported | |
| Inter-ocular difference ≥ 2 lines | 1.5% | 2.7% | 0.06 | |
| VA <6/12 | 0.6% | 1.8% | 0.02 | |
| Inter-ocular difference ≥ 2 lines | 1.1% | 2.0% | 0.05 (0.24)† | |
| VA ≤6/9 | 1.9% | 3.4% | 0.01 (0.16)† | |
| VA <6/12 | 0.7% | 1.3% | 0.11 (0.55)† | |
VA = Visual acuity.
* In brackets: 95% confidence interval, if reported in the publication.
† Adjustment for confounding factors like sex, highest level of maternal education, birth weight, family history of strabismus/amblyopia and duration of breastfeeding.